Algeta completes enrolment of 900 patients into phase III ALSYMPCA trial with Alpharadin
Primary endpoint is overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastases
Algeta ASA has completed enrolment of the targeted 900 patients into its ALSYMPCA phase III clinical trial with Alpharadin (radium-223 chloride).
The ALSYMPCA study (ALpharadin in SYMptomatic Prostate CAncer patients) is a double-blind randomized, placebo-controlled phase III clinical trial evaluating the potential of Alpharadin to treat castration-resistant prostate cancer (CRPC) patients with bone metastases. Bone metastases are the main cause of disability and death in patients with CRPC and approximately 90% of men with this disease have radiological evidence of bone metastasis.
The primary efficacy endpoint of ALSYMPCA is overall survival. The trial also evaluates both the safety profile of Alpharadin treatment and its impact on quality of life.
The trial began in June 2008 and is being conducted at more than 140 clinical centers worldwide, including 14 centers in the United States. Results of the trial are anticipated in 2012 and could allow a regulatory filing in 2012.
Alpharadin (radium-223 chloride) is being developed by Algeta and Bayer Schering Pharma AG. It is a first-in-class alpha-pharmaceutical that in Phase II trials showed a statistically significant improvement in overall survival compared to placebo (approximately 40% improvement, p=0.017, hazard ratio 0.48), a consistent improvement in disease-related biomarkers and pain, and a favorable side-effect profile.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.